期刊
INFLAMMATORY BOWEL DISEASES
卷 18, 期 1, 页码 152-160出版社
OXFORD UNIV PRESS INC
DOI: 10.1002/ibd.21870
关键词
Crohn's disease; treatment consensus; mucosal healing; bowel preservation; TNF antagonists; infliximab; biologics
资金
- Merck
- Sharp
- Dohme Corp., Whitehouse Station, NJ
- MSD
- Abbott
- Centocor
- Schering Canada
- Abbott Laboratories
- UCB
- SP
- Millenium
- Elan
- Proctor Gamble
- BMS Canada
Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据